Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Down 1.4 %

PULM opened at $2.09 on Tuesday. The firm has a market cap of $7.63 million, a PE ratio of -0.54 and a beta of 0.92. The business has a fifty day simple moving average of $1.84 and a 200-day simple moving average of $1.88. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $3.14.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. The company had revenue of $2.20 million for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%.

Institutional Investors Weigh In On Pulmatrix

Several large investors have recently modified their holdings of PULM. Citadel Advisors LLC bought a new stake in shares of Pulmatrix during the 2nd quarter worth $141,000. Mariner LLC purchased a new stake in shares of Pulmatrix in the fourth quarter valued at $97,000. Susquehanna International Group LLP purchased a new stake in shares of Pulmatrix in the first quarter valued at $73,000. Vanguard Group Inc. lifted its holdings in shares of Pulmatrix by 62.9% in the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 13,548 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Pulmatrix by 7.3% in the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,300 shares in the last quarter. 11.84% of the stock is owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.